Novo Nordisk A/S - share repurchase programme
11 Dezember 2023 - 2:27PM
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 11 December
2023 – On 6 November 2023, Novo Nordisk initiated a share
repurchase programme in accordance with Article 5 of Regulation No
596/2014 of the European Parliament and Council of 16 April 2014
(MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8
March 2016 (the "Safe Harbour Rules"). This programme is part of
the overall share repurchase programme of up to DKK 30 billion to
be executed during a 12-month period beginning 1 February 2023.
Under the programme initiated 6 November 2023, Novo Nordisk will
repurchase B shares for an amount up to DKK 4.1 billion in the
period from 7 November 2023 to 29 January 2024.
Since the announcement of the programme, the following
transactions have been made:
|
|
Number of B shares (of DKK 0.10) |
Average purchase price |
Transaction value, DKK |
|
Accumulated, last announcement |
2,103,000 |
|
1,469,059,557 |
|
04 December 2023 |
110,000 |
694.69 |
76,415,579 |
|
05 December 2023 |
110,000 |
688.28 |
75,711,171 |
|
06 December 2023 |
110,000 |
685.11 |
75,362,008 |
|
07 December 2023 |
115,000 |
672.63 |
77,352,233 |
|
08 December 2023 |
115,000 |
666.11 |
76,602,197 |
|
Accumulated under the programme |
2,663,000 |
|
1,850,502,745 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
50,667,054 B shares of DKK 0.10 as treasury shares, corresponding
to 1.1% of the share capital. The total amount of A and B shares of
DKK 0.10 in the company is 4,510,000,000 including treasury
shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 30 billion during a 12-month period beginning 1 February 2023.
As of 08 December 2023, Novo Nordisk has since 1 February 2023
repurchased a total of 46,770,778 B shares of DKK 0.10 at an
average share price of DKK 592.80 per B share of DKK 0.10 equal to
a transaction value of DKK 27,725,587,543.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 61,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Elizabeth
DeLuca (US)+1 609 580 9868edel@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3075 6656 azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 82 / 2023
- CA231211-Share-repurchase
- 20231211 Safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
